ALS drug trial halted early: what we learned about brain inflammation

NCT ID NCT04066244

Terminated Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called BLZ945 in 28 people with ALS to see if it could reduce brain inflammation. Researchers used special PET scans to measure inflammation. The study was terminated early, so the full results are not available, but it aimed to gather safety and biological data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BLZ945
What this could lead to: If successful, this could point toward a way to reduce brain inflammation in ALS, potentially slowing disease progression.
What could go wrong: This was a small, early-stage study that was terminated, so results are limited. It is unclear if BLZ945 is safe or effective for ALS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Novartis Investigative Site

Turku, 20520, Finland
Novartis Investigative Site

Stockholm, 14186, Sweden
Yale University School of Medicine

New Haven, Connecticut, 06520-8048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.